TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03960762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESP block (Group ESP)
Description: In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SAP block (Group SAP)
Description: In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
Study: NCT06408636

Intervention type: OTHER
Intervention: Cardiac MRI
Description: All selected patients completed a cardiac magnetic resonance examination without other interventions.
Study: NCT02319603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose WenXin keli
Description: Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
Study: NCT03749018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Give IV
Study: NCT02319603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose WenXin keli
Description: High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
Study: NCT02884986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120mg of placebo
Study: NCT04902963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PE tube
Description: Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
Study: NCT06103422

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole mouth taste tests
Description: Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Localized taste tests
Description: Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Localized taste tests
Description: Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
Study: NCT05781529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge augmentation with injectable platelets rich fibrin
Description: Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
Study: NCT02529956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB4940
Description: * Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use
Study: NCT01258985

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: 12 weeks of Tai Chi

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
Study: NCT04361331

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib combined with gemox
Description: Arm2: Lenvatinib + gemox

Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab combined with lenvatinib
Description: Toripalimab combined with lenvatinib
Study: NCT02980458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone 500Mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 500 MG Oral Tablet [Ferriprox]
Study: NCT02842385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
Study: NCT03030534

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Educational package and software package
Description: Using Information and communication technology to deliver health promoting activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion tips
Description: Give general information on health promotion
Study: NCT03906708

Intervention type: OTHER
Intervention: Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Description: Infant lung function testing
Study: NCT02114944

Intervention type: DEVICE
Intervention: NIV
Description: Patients treated, as per attending physician's decision, with noninvasive ventilation

Intervention type: DEVICE
Intervention: CPAP
Description: Patient treated, as per attending physician's decision, with CPAP
Study: NCT03728985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Description: Endovascular Aortic Stent-Graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis
Description: Endovascular Aortic Stent-Graft
Study: NCT02114944

Intervention type: DEVICE
Intervention: Standard oxygen
Description: Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV

Intervention type: DEVICE
Intervention: Standard oxygen
Description: Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV

Intervention type: DEVICE
Intervention: Standard oxygen
Description: Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV

Intervention type: DEVICE
Intervention: HFNC
Description: Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP

Intervention type: DEVICE
Intervention: HFNC
Description: Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP

Intervention type: DEVICE
Intervention: HFNC
Description: Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
Study: NCT01016041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus stent
Description: stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel stent
Description: stenting
Study: NCT04644445

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bariatric Full Liquid Diet
Description: Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
Study: NCT01139840

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2
Description: Study Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Study Supplement
Study: NCT04369170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prosthesis connected directly to the implants
Description: dental prostheses connected directly to the dental implants

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermediate abutment
Description: dental prostheses connected with an intermediate abutment to the implant
Study: NCT02514317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT04019418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin (carbohydrate)
Description: A drink containing 300ml of water and 75g of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin (carbohydrate)
Description: A drink containing 300ml of water and 75g of maltodextrin
Study: NCT02420314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: * Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: * Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: * Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts
Study: NCT06211218

Intervention type: DIAGNOSTIC_TEST
Intervention: Cornea diseases diagnosed by artificial intelligence algorithm
Description: An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
Study: NCT04331951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted biopsy within Sydney protocol
Description: Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
Study: NCT02594579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
Study: NCT04286776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct electrical stimulation
Description: Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
Study: NCT00680914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A (Synflorix)
Description: 3 doses administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 3 doses administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Hiberix™
Description: 3 doses administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hiberix™
Description: 3 doses administered intramuscularly.
Study: NCT00389480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (formerly DB-67)
Description: infusion daily x 5 days, every 21 days
Study: NCT01663363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK correction of myopic refractive errors
Description: Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
Study: NCT06036264

Intervention type: OTHER
Intervention: Collected of Datas
Description: age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)

Intervention type: OTHER
Intervention: Collected of Datas
Description: age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)

Intervention type: OTHER
Intervention: semi-structured interview
Description: Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
Study: NCT01091883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: MR Guided Focused Ultrasound

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: External Beam Radiation
Study: NCT05995561

Intervention type: OTHER
Intervention: no intervention is planned.
Description: no intervention is planned.
Study: NCT00257933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone high dose
Description: 4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone lower dose
Description: 2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
Study: NCT04097665

Intervention type: DEVICE
Intervention: indocyanine green angiography
Description: All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
Study: NCT04019418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes on a cycle ergometer working at 75% VO2 max

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 30 minutes on a cycle ergometer working at 75% VO2 max
Study: NCT02011529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEAMcare treatment of diabetes
Description: TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
Study: NCT05781529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge augmentation with hyaluronic acid
Description: Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge augmentation with xenograft
Description: Xenograft is added alone as a active compatator
Study: NCT04287751

Intervention type: DEVICE
Group type: OTHER
Intervention: CheckMeO2 Oximeter
Description: Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
Study: NCT01630499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Lifestyle Intervention (TLI)
Description: The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
Study: NCT01550887

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention will be performed on this study
Study: NCT04019418

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: 30 minutes laying on a bed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 30 minutes laying on a bed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: A drink containing 300ml of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A drink containing 300ml of water
Study: NCT04138888

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.

Intervention type: DRUG
Group type: OTHER
Intervention: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use
Description: Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Study: NCT04185532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound ACL brace and physioterapy
Description: Usage of rebound ACL brace and physioterapy supervised by physioterapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physioterapy
Description: Physioterapy supervised by physioterapist